Oxford Biomedica Plc

Oxford Biomedica Plc

Oxford Biomedica Plc

Overview
Date Founded

1996

Headquarters

WINDRUSH COURT, TRANSPORT WAY, OXFORD, OX4 6LT

Type of Company

Public

Employees (Worldwide)

554

Industries

Biotechnology
Pharmaceuticals

Company Description

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through following segments: Platform and Product. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Oxford Biomedica Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Director, Chief Executive Officer

Chief Financial Officer & Director

Secretary & General Counsel

Chief Scientific Officer

Chief Technical Officer

Head, Clinical Analysis

Head, Intellectual Property & Contracts

Head-Quality

Chief Business Officer

Chief Medical Officer

Board of Directors

Vice Chairman at Vlerick Leuven Gent Management School

Former Partner at Deloitte LLP - United Kingdom

Managing Partner at Pivotal Bioventure Partners Investment Advisor LLC

Executive Director, Chief Executive Officer at Oxford Biomedica Plc

Partner & Head of NOVO Growth at Novo Principal Investments

Founder at OxStem Ltd.

Astra USA, Inc.

Chief Financial Officer & Director at Oxford Biomedica Plc

President, Chief Executive Officer & Director at Platelet BioGenesis, Inc.

Former Chief Executive Officer at PureDepth, Inc.

Paths to Oxford Biomedica Plc
Potential Connections via
Relationship Science
You
Oxford Biomedica Plc
Owners & Shareholders
Details Hidden

Vulpes Investment Management is a long-term investor which aims to generate real capital appreciation and income through concentration on a small number of compelling investment opportunities. The firm’s investment focus is Agriculture and German Real Estate. For long-term capital growth, Vulpes Investment Management invests across Life Sciences, Disruptive Technologies and other Private Equity style opportunities.

Details Hidden

LIL’s investment process includes the objective, strategy, implementation and review. The firm’s fund management teams use distinct and rigorous investment process in managing their funds. They invest worldwide and manage generalist, diversified portfolios spread across various sectors, managed both on a global and regional basis. LIL’s investment team seeks to create value for shareholders over the medium- to long-term, utilizing a top-down approach for asset allocation and a bottom-up approach for selecting ordinary shares. They monitor performance against relevant indexes, but do not track any index. The firm is primarily an equity investor.

Details Hidden

CGWL is an active, long-term investor which offers clients an access to a wide range of portfolio building and management resources, supported by rigorous, robust and highly analytical investment process includes in-depth research, in-house resources and insights into local and international markets. The firm’s discretionary portfolios invest in individual stocks and bonds, and other alternative asset classes. They also invest in third party investment funds, for added diversification and access to a wide range of investment styles and strategies. CGWL provides a range of different investments, including securities, equities, funds, exchange-traded funds (ETFs), investment trusts, venture capital trusts (VCTs), enterprise investment schemes (EISs), alternatives, bonds and cash.

Recent Transactions
Details Hidden

Oxford Biomedica Plc issued GBP Ordinary Shares

Details Hidden

Oxford Biomedica Plc issued GBP Ordinary Shares

Details Hidden

Oxford Biomedica Plc issued GBP Ordinary Shares

Transaction Advisors
Auditor

Advised onOxford Biomedica Plc issued GBP Ordinary Shares

Broker

Advised onOxford Biomedica Plc issued GBP Ordinary Shares

Broker

Advised onOxford Biomedica Plc issued GBP Ordinary Shares

Advisors & Consultants
Legal Advisor

Partner at Fenwick & West LLP

Clients

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2019
Market Capitalization
$1.14B
Total Enterprise Value
$584M
Earnings Per Share
$-0.28
EBITDAMargin
-12.39%
Enterprise Value / Sales
7.16x
TEVNet Income
-28.53x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
32.12%
Five Year Compounded Annual Growth Rate Of Revenue
36.3%
Revenue
$81.6M
Net Profit
$-20.5M
EBITDA
$-10.1M
Total Debt
$10.7M
Total Equity
$96.3M
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oxford Biomedica Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oxford Biomedica Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Oxford Biomedica Plc.